Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Earnings Results, Beats Expectations By $0.11 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.11, Zacks reports. Oramed Pharmaceuticals had a negative net margin of 362.38% and a negative return on equity of 41.18%. The company had revenue of $0.67 million during the quarter.

ORMP traded down $0.18 during trading on Friday, hitting $5.32. 178,056 shares of the stock traded hands, compared to its average volume of 133,717. The firm has a market capitalization of $83.51 million, a P/E ratio of 6.49 and a beta of 1.42. The firm has a 50-day moving average of $4.72 and a 200 day moving average of $3.62. Oramed Pharmaceuticals has a 12-month low of $2.32 and a 12-month high of $6.05.

A number of equities research analysts have recently issued reports on ORMP shares. ValuEngine cut shares of Oramed Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, December 30th. HC Wainwright set a $20.00 price target on shares of Oramed Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, September 18th.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.

See Also: Why does a company issue an IPO?

Earnings History for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply